Abstract
Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing everyother- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
Keywords: Statins, intolerance, muscle symptoms, transaminases, creatine kinase, new-onset diabetes, side effects, ezetimibe, proprotein convertase subtilisin kexin 9 inhibitors, non-statin lipid-lowering drugs.
Current Vascular Pharmacology
Title:Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Volume: 14 Issue: 6
Author(s): Niki Katsiki, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Statins, intolerance, muscle symptoms, transaminases, creatine kinase, new-onset diabetes, side effects, ezetimibe, proprotein convertase subtilisin kexin 9 inhibitors, non-statin lipid-lowering drugs.
Abstract: Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing everyother- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
Export Options
About this article
Cite this article as:
Katsiki Niki, Athyros G. Vasilios and Karagiannis Asterios, Exploring the Management of Statin Intolerant Patients: 2016 and Beyond, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160226150028
DOI https://dx.doi.org/10.2174/1570161114666160226150028 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Role of TRP Channels in Cough Hypersensitivity?
Current Respiratory Medicine Reviews Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Macrophage Polarization as a Therapeutic Target in Myocardial Infarction
Current Drug Targets Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Role of Intra-Luminal Pressure in Regulating PBF in the Fetus and After Birth
Current Pediatric Reviews Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry The IGF-I Signaling Pathway
Current Pharmaceutical Design Atheroma Burden and Morphology in Women
Current Pharmaceutical Design Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews